Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

A Prognostic Model to Identify Patients with Advanced Pancreas Adenocarcinoma Who Could Benefit from Second-line Chemotherapy

Authors
Kim, Seung TaeChoi, Yoon JiPark, Kyong HwaOh, Sang CheulSeo, Jae HongShin, Sang WonKim, Jun SukKim, Yeul Hong
Issue Date
Mar-2012
Publisher
ELSEVIER SCIENCE LONDON
Keywords
Pancreatic adenocarcinoma; prognostic model; second-line chemotherapy
Citation
CLINICAL ONCOLOGY, v.24, no.2, pp.105 - 111
Indexed
SCIE
SCOPUS
Journal Title
CLINICAL ONCOLOGY
Volume
24
Number
2
Start Page
105
End Page
111
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/105360
DOI
10.1016/j.clon.2011.02.005
ISSN
0936-6555
Abstract
Aims: The role of salvage chemotherapy after first-line therapy in advanced pancreatic cancer has not yet been established. We intended to identify prognostic factors for long-term survival of advanced pancreatic adenocarcinoma patients with second-line chemotherapy and to devise a prognostic model of clinical parameters. Patients and methods: We analysed 90 patients who had received second-line chemotherapy after the failure of first-line therapy in recurrent or metastatic pancreatic adenocarcinoma between August 2003 and December 2008. Results: The median age at the time of second-line chemotherapy was 61.9 years (range 39.8-74.9) and the median Eastern Cooperative Oncology Group (ECOG) performance status was 1 (0-2). Median progression-free survival and overall survival for second-line chemotherapy were 2.1 and 4.5 months, respectively, with an overall response rate of 10%. In multivariate analysis, an ECOG performance status of 2 or more, non-responder for first-line chemotherapy and albumin level of <3.5 mg/dl were independent prognostic factors for decreased overall survival for all 90 patients. Overall survival was estimated based on the number of adverse prognostic factors: zero or one (good prognostic group), two (intermediate group) or three (poor prognostic group). The median overall survival for good (n = 50), intermediate (n = 24) and poor (n = 16) prognostic groups was 5.5, 3.3 and 2.1 months, respectively (P <0.001). Conclusion: Our result suggests that second-line chemotherapy may be beneficial for overall survival in patients with ECOG performance status 0-1, albumin level >= 3.5 mg/dl and response to first-line chemotherapy. (C) 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles
Graduate School > Department of Biomedical Sciences > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Shin, Sang Won photo

Shin, Sang Won
College of Medicine (Department of Medical Science)
Read more

Altmetrics

Total Views & Downloads

BROWSE